期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 61, 期 13, 页码 5512-5524出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01653
关键词
-
资金
- ALSAC
- Office of Naval Research [N000140911014, N000141210191, N000141210775, N000141612315]
- National Institutes of Health [2R01DC006471, 1R01DC015010-01A1, 1R01DC015444-01, 1R21DC013879-01, P30CA21765]
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006471, R01DC015444, R21DC013879, R01DC015010] Funding Source: NIH RePORTER
Cisplatin is a highly effective treatment for malignant cancers and has become a cornerstone in chemotherapeutic regimens. Unfortunately, its use in the clinic is often coupled with a high incidence of severe hearing loss. Over the past few decades, enormous effort has been put forth to find protective agents that selectively protect against the ototoxic side effects of cisplatin and do not interfere with its antitumoral activity. Many therapies have been successful in preclinical work, but only a few have shown any protection in the clinic, and none have been approved by the FDA This review summarizes the clinical and preclinical studies of the most effective small-molecule candidates currently in clinical trials, while also detailing their molecular mechanisms of action, to gam insight for future drug development in the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据